{
  "package" : "hl7.fhir.r4.core@4.0.1",
  "definition" : null,
  "system" : "http://terminology.hl7.org/CodeSystem/v2-0078",
  "property" : [ {
    "_uri" : "http://hl7.org/fhir/concept-properties#status",
    "code" : "status",
    "valueCode" : "deprecated"
  }, {
    "_uri" : "http://hl7.org/fhir/concept-properties#deprecationDate",
    "code" : "deprecationDate",
    "valueDateTime" : "2015-09"
  } ],
  "codesystem" : "c1f03c25-12cd-5f31-bda4-8fbd4598ab7d",
  "concept_id" : "d530f314-5614-53c1-8d53-7837ca1dd62d",
  "ancestors" : {
    "I" : 0
  },
  "extension" : [ {
    "url" : "http://hl7.org/fhir/StructureDefinition/codesystem-concept-comments",
    "valueString" : "Bacterial strain inhibited in vitro by a\r\nconcentration of an antimicrobial agent that is associated with\r\nuncertain therapeutic effect.\r\nReference: CLSI (http://www.clsi.org/Content/NavigationMenu/Resources/HarmonizedTerminologyDatabase/Harmonized_Terminolo.htm)\r\nProjects: ISO 20776-1, ISO 20776-2\r\n\r\nNote 1: Bacterial strains are categorized as intermediate by applying the appropriate breakpoints in a defined phenotypic test system.\r\n\r\nNote 2: This class of susceptibility implies that an infection due to the\r\nisolate can be appropriately treated in body sites where the drugs are physiologically concentrated or when a high dosage of drug can be used.\r\n\r\nNote 3: This class also indicates a “buffer zone,” to prevent small, uncontrolled, technical factors from causing major discrepancies in interpretations.\r\n\r\nNote 4: These breakpoints can be altered due to changes in circumstances (e.g., changes in commonly used drug dosages, emergence of new resistance mechanisms).",
    "_valueString" : {
      "extension" : [ {
        "url" : "http://hl7.org/fhir/StructureDefinition/translation",
        "extension" : [ {
          "url" : "lang",
          "valueCode" : "nl"
        }, {
          "url" : "content",
          "valueString" : "Bacteriële stam geblokkeerd door in vitro concentratie van een anti-bacteriële agens die is gekoppeld aan een onzekere kans op therapeutisch effect. Referentie: CLSI (http://www.clsi.org/Content/NavigationMenu/Resources/HarmonizedTerminologyDatabase/Harmonized_Ter"
        } ]
      } ]
    }
  } ],
  "id" : "374df4b8-e036-47e3-96b3-5728099e7f7c",
  "code" : "I",
  "display" : "Intermediate",
  "designation" : [ {
    "use" : {
      "code" : "display",
      "system" : "http://terminology.hl7.org/CodeSystem/designation-usage"
    },
    "value" : "Intermediär",
    "language" : "de"
  }, {
    "use" : {
      "code" : "display",
      "system" : "http://terminology.hl7.org/CodeSystem/designation-usage"
    },
    "value" : "Gemiddeld",
    "language" : "nl"
  } ],
  "version" : "2.9"
}